GREGOIRE, Céline ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'hématologie clinique
BRIQUET, Alexandra ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Laboratoire de thérapie cellulaire et génique (LTCG)
PIRENNE, Caroline
LECHANTEUR, Chantal ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Laboratoire de thérapie cellulaire et génique (LTCG)
LOUIS, Edouard ✱; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de gastroentérologie, hépatologie, onco. digestive
BEGUIN, Yves ✱; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'hématologie clinique
✱ These authors have contributed equally to this work.
Language :
English
Title :
Allogeneic mesenchymal stromal cells for refractory luminal Crohn's disease: A phase I-II study.
Grégoire, C., Lechanteur, C., Briquet, A., Baudoux, E., Baron, F., Louis, E., et al. Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases. Aliment Pharmacol Ther 45 (2017), 205–221.
Garcia-Olmo, D., Herreros, D., Pascual, I., Pascual, J.A., Del-Valle, E., Zorrilla, J., et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 52 (2009), 79–86.
Panés, J., García-Olmo, D., Van Assche, G., Colombel, J.F., Reinisch, W., Baumgart, D.C., et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet 388 (2016), 1281–1290.
Lechanteur, C., Briquet, A., Giet, O., Delloye, O., Baudoux, E., Beguin, Y., Clinical-scale expansion of mesenchymal stromal cells: a large banking experience. J Trans Med, 14, 2016 p145.
Forbes, G.M., Sturm, M.J., Leong, R.W., Sparrow, M.P., Segarajasingam, D., Cummins, A.G., et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin Gastroenterol Hepatol 12 (2014), 64–71.
Dhere, T., Copland, I., Garcia, M., Chiang, K.Y., Chinnadurai, R., Prasad, M., et al. The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn's disease – a phase 1 trial with three doses. Aliment Pharmacol Ther 44 (2016), 471–481.
Takayama, T., Kamada, N., Chinen, H., Okamoto, S., Kitazume, M.T., Chang, J., et al. Imbalance of NKp44(+)NKp46(−) and NKp44(−)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology 139 (2010), 882–892.
Liao, C.-M., Zimmer, M.I., Wang, C.-R., The functions of type I and type II natural killer T cells in inflammatory bowel diseases. Inflamm Bowel Dis 19 (2013), 1330–1338.
Prigione, I., Benvenuto, F., Bocca, P., Battistini, L., Uccelli, A., Pistoia, V., Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells 27 (2009), 693–702.
Galleu, A., Riffo-Vasquez, Y., Trento, C., Lomas, C., Dolcetti, L., Cheung, T.S., et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci Trans Med, 9(416), 2017.
